by Carolyn Thomas ♥ @HeartSisters
You’d hardly expect a physician who spends his life trying to cure cancer to suddenly shift gears and suggest that maybe, just maybe, we should “stop trying”. But it turns out that New Jersey oncologist Dr. James Salwitz agrees with a review of data published in the September 2012 issue of Lancet Oncology, entitled “First Do No Harm: Counting the Cost of Chasing Drug Efficacy.” *
An accompanying Lancet editorial suggests that during the 10 years between 2000 and 2010, “many new cancer drugs produced marginal extensions in survival and simultaneously increased risk of treatment-associated death and side effects.” This compelled Dr. Salwitz to write: Continue reading
by Carolyn Thomas
When Britain’s Dr. Richard Smith speaks, I like to listen. He’s a former editor of the British Medical Journal (and also, coincidentally, a former med school prof who in 2001 resigned from his University of Nottingham teaching post in protest over the school’s acceptance of a £3.8 million gift from a tobacco company). Dr. Smith now offers a cheeky yet revealing overview of what’s wrong with medicine. In fact, I feel compelled to share with you his recent BMJ article, published shortly after returning from the World Cardiology Congress in Dubai. He writes:
“Doctors are not interested in health“.
by Carolyn Thomas
A recent study from Johns Hopkins Hospital may be very bad news for drug companies that make statin drugs for cholesterol management. Statins, of course, are considered the darlings of Big Pharma. I’ve heard cardiologists joke (at least, I think they were joking) that statins are so fabulous at lowering our LDL (bad) cholesterol that we should be putting the drugs into our drinking water.
Virtually all heart attack survivors are now routinely prescribed statins (whether they have high cholesterol or not) and there’s a major marketing push for docs to prescribe statins as cardiovascular preventive therapy for virtually all adults, particularly to reduce blood levels of the inflammatory byproducts called C-reactive protein. But the Johns Hopkins study lead investigator Dr. Michael Blaha has this important new warning: Continue reading